Literature DB >> 10214973

Inhibition of beta-amyloid cytotoxicity by midkine.

G S Yu1, J Hu, H Nakagawa.   

Abstract

Midkine (MK) is a neurotrophic and angiogenic growth factor whose expression occurs mainly in fetus. It was reported that MK was present in senile plaques of Alzheimer's disease (AD). To investigate the role of MK during amyloid plaques formation in AD, we examined the in vitro effect of MK on Abeta aggregation and Abeta-induced cytotoxicity. We found that incubation of MK with Abeta resulted in the formation of MK/Abeta complexes. The C-terminus of MK (60-121) played a similar role as the full length MK in complex formation. This interaction of MK and Abeta demonstrated significant inhibition on Abeta self-aggregation. MK also inhibited the cytotoxicity of Abeta on PC12h cells. These findings suggest that MK protects the cells from Abeta-induced cytotoxicity through its complex formation with Abeta. MK is probably expressed to prevent cell death in AD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10214973     DOI: 10.1016/s0304-3940(98)00685-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

Review 1.  Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.

Authors:  G Herradón; C Pérez-García
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

2.  Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson's disease.

Authors:  Rui D S Prediger; Argelia E Rojas-Mayorquin; Aderbal S Aguiar; Caroline Chevarin; Raymond Mongeau; Michel Hamon; Laurence Lanfumey; Elaine Del Bel; Hisako Muramatsu; José Courty; Rita Raisman-Vozari
Journal:  J Neural Transm (Vienna)       Date:  2011-02-08       Impact factor: 3.575

3.  Per-6-substituted beta-cyclodextrin libraries inhibit formation of beta-amyloid-peptide (A beta)-derived, soluble oligomers.

Authors:  Jiaxin Yu; Lara Bakhos; Lei Chang; Mark J Holterman; William L Klein; Duane L Venton
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

Review 4.  Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.

Authors:  Takashi Muramatsu
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

5.  Midkine as a factor to counteract the deposition of amyloid β-peptide plaques: in vitro analysis and examination in knockout mice.

Authors:  Hisako Muramatsu; Katsunori Yokoi; Lan Chen; Keiko Ichihara-Tanaka; Terutoshi Kimura; Takashi Muramatsu
Journal:  Int Arch Med       Date:  2011-01-12

Review 6.  Midkine: a promising molecule for drug development to treat diseases of the central nervous system.

Authors:  Takashi Muramatsu
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

7.  Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology.

Authors:  Frances M Potjewyd; Joel K Annor-Gyamfi; Jeffrey Aubé; Shaoyou Chu; Ivie L Conlon; Kevin J Frankowski; Shiva K R Guduru; Brian P Hardy; Megan D Hopkins; Chizuru Kinoshita; Dmitri B Kireev; Emily R Mason; Charles T Moerk; Felix Nwogbo; Kenneth H Pearce; Timothy I Richardson; David A Rogers; Disha M Soni; Michael Stashko; Xiaodong Wang; Carrow Wells; Timothy M Willson; Stephen V Frye; Jessica E Young; Alison D Axtman
Journal:  Alzheimers Dement (N Y)       Date:  2022-04-12

8.  Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas.

Authors:  S Ikematsu; A Nakagawara; Y Nakamura; S Sakuma; K Wakai; T Muramatsu; K Kadomatsu
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.